TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
UBS Group AG and its related bodies corporate have increased their voting power in Mayne Pharma Group Limited, a company in the pharmaceutical industry, from 5.77% to 6.83% as of May 29, 2025. This change in substantial holding reflects UBS’s strategic interest in Mayne Pharma, potentially impacting the company’s market dynamics and signaling a shift in shareholder influence and control.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
YTD Price Performance: -0.40%
Average Trading Volume: 915,341
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$402.2M
For an in-depth examination of MYX stock, go to TipRanks’ Stock Analysis page.